Latest Headlines

Latest Headlines

Analyst sees big things for Allergan, Amgen despite slow growth in China and biosimilar pressures

The media blitz over jacked-up drug prices and concerns over slowing growth in China may have temporarily kicked the breath out of pharma valuations, but some analysts think the concerns will be short-lived and a return to growth is inevitable.

Novartis targets Amgen's Enbrel with second biosimilar app

Right now, Novartis' Sandoz has the only biosimilar on the U.S. market. And it's looking to make it two.

Novartis comes for Enbrel in latest biosimilar shot at Amgen

A month removed from launching the U.S.'s first biosimilar, Novartis is again setting sights on an Amgen cash cow, lining up for FDA approval with a copy of the blockbuster Enbrel.

Citing cost, top doctors back limits on PCSK9 cholesterol fighters

Payers unhappy with the cost of new PCSK9 drugs are getting some ammo, as top U.S. physicians are recommending against using the drugs in a large patient pool.

Next-gen oncolytics upstart Replimune grabs a $30M transatlantic venture round

One of the original players in the development of Amgen's cancer therapy talimogene laherparepvec (T-Vec), now up under review at the FDA, has started a new biotech focused on oncolytics drug development. And the U.K. company attracted a $30 million startup round from a transatlantic group of venture players to get started with a splash.

Amgen and Allergan clear Phase III with an Avastin biosimilar, looking to unseat a blockbuster

Partners Amgen and Allergan say their knockoff of Roche's blockbuster Avastin proved itself on par with its reference product, putting the pair a step closer to biting into the cancer drug's billions in annual revenue.

Building its cardio drug portfolio, Amgen bags Dezima in $1.55B deal

Amgen has struck a deal to buy in an experimental midstage LDL treatment in a $1.55 billion deal. Amgen is acquiring Dutch biotech Dezima for $300 million up front and $1.25 billion in milestones, tackling another potential blockbuster franchise that has spurred billions of dollars in often frustrating research programs.

Amgen bets up to $1.7B on Xencor's antibody technology

Amgen is teaming up with Xencor through a heavily back-loaded deal worth as much as $1.7 billion, collaborating on 6 early-stage programs in immuno-oncology and inflammation.

Patrick Soon-Shiong plucks another cancer drug out of Amgen's pipeline

Nine months after Patrick Soon-Shiong struck a deal to acquire the global rights to a failed cancer drug at Amgen, the biotech billionaire has come back for a second oncology program. Soon-Shiong's NantPharma has in-licensed Amgen's AMG 337, a mid-stage MET inhibitor in the clinic for gastric cancer.

AstraZeneca scoops up Amgen U.S. plant to boost biologics capacity

When AstraZeneca announced plans last spring to build a $285 million biologics facility in Sweden, it said it would be the first of several investments in its large-molecule manufacturing capacity that it would be making. Now the U.K. drugmaker says it has acquired a biologics plant in Colorado from Amgen.